---
title: "Abbott Laboratories jumps after six straight sessions of losses"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298958628.md"
description: "Abbott Laboratories (ABT) rose 1.21% to $103.18, ending six consecutive days of losses after agreeing to pay the DOJ $385 million to resolve claims related to its 2022 baby formula recall. The company admitted no wrongdoing. Despite a 21% year-over-year decline and a Seeking Alpha 'Hold' rating due to valuation concerns, Wall Street maintains a consensus 'Buy' rating, citing renewed momentum in nutrition, diagnostics, and medical devices."
datetime: "2026-09-14T20:16:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298958628.md)
  - [en](https://longbridge.com/en/news/298958628.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298958628.md)
generator: "portal-rs"
---

# Abbott Laboratories jumps after six straight sessions of losses


### Related Stocks

- [ABT.US](https://longbridge.com/en/quote/ABT.US.md)

## Related News & Research

- [Abbott agrees to settle DOJ lawsuit over baby formula plant contamination](https://longbridge.com/en/news/299081753.md)
- [Abbott reaches agreement with Department of Justice to resolve claims relating to 2022 infant formula recall | ABT Stock News](https://longbridge.com/en/news/298942114.md)
- ['Don't Get Too Excited,' Says Investor About META Stock](https://longbridge.com/en/news/299670642.md)
- [ANALYSIS-Big to get bigger: India's UPI fee shift to entrench dominant incumbents](https://longbridge.com/en/news/299727281.md)
- [Viking Therapeutics' obesity drug shows durable weight-loss benefit, shares jump](https://longbridge.com/en/news/299757599.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**